19:51:38 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Aurora Spine Corp
Symbol ASG
Shares Issued 15,686,709
Close 2014-10-20 C$ 1.44
Market Cap C$ 22,588,861
Recent Sedar Documents

Aurora Spine enters distribution deal for Sentio MMG

2014-10-21 09:13 ET - News Release

Mr. Trent Northcutt reports

AURORA SPINE ANNOUNCES GLOBAL DISTRIBUTION AGREEMENT FOR SENTIO MMG(R) NERVE MAPPING SYSTEM

Aurora Spine Corp. has entered into a worldwide distribution and co-marketing agreement with Sentio LLC to distribute the Sentio MMG nerve-mapping system.

Sentio has pioneered a game-changing method for mapping nerve location, resulting in improved technology for surgeons to use as compared with traditional techniques. Sentio MMG is a surgical access tool used to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.

"This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies," said Trent J. Northcutt, president and chief executive officer of Aurora Spine. "We are excited about our relationship with Sentio MMG in conjunction with our VOX MIS [minimally invasive surgical] lateral interbody system featuring TiNano. The Sentio system was specifically designed to facilitate safe MMG monitoring during any MIS spine surgery. Aurora and Sentio share a vision to improve spine patient outcomes, drive continued surgeon interest and bolster relevance as key innovators in spine."

"Aurora's MIS, tech-company culture fits extremely well with Sentio. We share a common ethos that will help drive both organizations to success as we co-market our technologies," said Sean Parker, Sentio's vice-president of market development.

Sentio MMG smart sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical twitch associated with muscle contraction. The result is an intuitive, surgeon-directed tool for establishing safe access in a variety of surgical applications.

Sentio is currently cleared for use in the United States by the U.S. Food and Drug Administration to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. Sentio MMG has a CE mark for use in the European Union and other markets.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.